What does the Cruise and Blast protocol mean for Testosterone Propionate users?

Cruise and Blast is a long-term androgen periodisation strategy alternating between a low-dose cruise phase — maintaining testosterone at near-physiological levels — and a higher-dose blast phase designed to maximise hypertrophic stimulus. Testosterone Propionate is favoured for this framework because its short ester clearance window allows dose escalation and reduction to reflect in plasma within days, enabling genuinely distinct phase boundaries rather than pharmacokinetic overlap.

How long should the cruise phase last before switching back to a blast?

Most structured Cruise & Blast programmes allocate cruise phases of eight to twelve weeks to allow meaningful hormonal and cardiovascular biomarker recovery between blasts. Haematocrit normalisation and LDL-C stabilisation are commonly used clinical markers to gauge cruise phase adequacy before re-escalation. With propionate, a twelve-week cruise followed by an eight-to-ten-week blast represents a well-documented periodisation ratio in performance-medicine literature.

When is the right time to transition from a blast back to a cruise with NordiTest P?

The transition from blast to cruise is typically triggered either by a pre-planned cycle calendar or by monitoring markers such as rising haematocrit, elevated blood pressure, or subjective recovery decline. Because NordiTest P contains the short propionate ester, the dose reduction takes effect within two to three injection intervals, allowing athletes to enter cruise-level plasma concentrations rapidly without a prolonged washout window required by depot esters.

How does NordiTest P's 150 mg/ml concentration benefit frequent injections during a blast phase?

At 150 mg/ml — the highest concentration in this product group — each injection delivers more active compound per millilitre of oil, reducing the total volume administered per session. For athletes injecting EOD or daily during a blast, this translates to reduced injection-site accumulation and lower local tissue stress compared to 100 mg/ml formulations requiring proportionally larger draws to achieve the same dose.

How should NordiTest P 10 ml vials be stored and handled for multi-week cruise and blast protocols?

Store NordiTest P vials at room temperature between 15–25 °C, away from direct light and moisture; refrigeration is not required but the vial should never be frozen. Once punctured, standard multi-dose vial sterility guidelines recommend use within 28 days with each draw executed using a fresh sterile needle to maintain septum integrity. An insulin syringe can accurately measure the 0.1 ml increments that correspond to 15 mg at this concentration. (2) angle_used

Advanced Formula

Nordi Pharma

NordiTest P 150mg/ml 10ml Vial by Nordi Pharma

Name: NordiTest P 150mg/ml 10ml Vial by Nordi Pharma
Brand: Nordi Pharma
SKU: INJ-TPRO-NOR-150-016
Price: 37.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

NordiTest P is a high-concentration Testosterone Propionate injectable at 150 mg/ml per 10 ml vial, purpose-built for athletes who structure their androgen exposure around defined Cruise & Blast phases requiring precise, rapid-acting dose control. The short propionate ester enables clean transitions between a low-dose cruise maintenance window and a higher-intensity blast phase without the prolonged accumulation lag associated with longer esters. Quality assurance at Nordi Pharma is enforced through HPLC potency verification and LAL endotoxin assay sign-off on every finished batch before release.

€37.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Rapid dose-response kinetics allow clean phase transitions between cruise and blast windows without prolonged pharmacokinetic overlap.
150 mg/ml concentration delivers meaningful androgen load in a reduced oil volume, minimising injection-site burden during frequent blast-phase administration.
Short ester clearance timeline gives athletes granular control over weekly androgen escalation and de-escalation across a structured Cruise & Blast calendar.
Analytically confirmed concentration via HPLC batch verification ensures consistent dose delivery across every draw from a 10 ml vial.
Endotoxin load confirmed by LAL assay on each batch, supporting frequent administration safety requirements of long-duration cruise-blast programmes.
Compatible with multi-compound blast configurations where propionate serves as the primary androgenic backbone with a predictable clearance profile.

Phase	Weekly Dose	Injection Frequency	Volume per Injection at 150 mg/ml	Note
Cruise	100–150 mg	3× per week (e.g. Mon/Wed/Fri)	~0.22–0.33 ml	Maintain near-physiological testosterone levels; monitor haematocrit and lipids quarterly.
Blast (moderate)	300–400 mg	EOD	~0.44–0.57 ml	Supra-physiological phase for hypertrophic stimulus; run 8–12 weeks before returning to cruise.
Blast (advanced)	450–600 mg	EOD or daily	~0.43–0.57 ml daily	Higher androgen exposure warrants closer cardiovascular and hormonal biomarker monitoring.
Cruise-to-Blast Transition	Incrementally +50 mg/week over 2–3 intervals	As per target blast schedule	Step-up per target dose	Gradual escalation avoids abrupt plasma spikes; propionate's short ester propagates each step within days.
Blast-to-Cruise Wind-Down	Step down over 2 injection intervals	3× per week	Reducing to cruise volume	Propionate clears within days, enabling rapid re-entry into cruise without depot accumulation.

Key takeaways

Structure blast and cruise phases using propionate's rapid dose-adjustment kinetics.
Leverage 150 mg/ml concentration to minimise injection volume during frequent blast dosing.
Monitor haematocrit and LDL-C as objective cruise-phase readiness markers.
Transition from blast to cruise across two or three injection intervals for controlled de-escalation.
Confirm each batch's potency via Nordi Pharma's HPLC verification before administration.

Cruise & Blast Protocol Engineering with Testosterone Propionate

NordiTest P is a fast-acting testosterone injectable that centres the Cruise & Blast methodology by allowing dose escalation and de-escalation to propagate through plasma within days rather than weeks. The Cruise & Blast framework divides long-term androgen use into two alternating modes: a cruise phase maintains circulating testosterone at a physiological or near-physiological ceiling, typically 100–200 mg per week, while a blast phase elevates total weekly androgen load — often 300–500 mg per week — to drive accelerated hypertrophy. Compared to longer-ester testosterone formulations such as enanthate or cypionate, propionate's abbreviated ester chain allows a user to enter and exit a blast with a transitional lag measured in days, not weeks, granting genuine phase separation.

Phase Mechanics: How Propionate Enables Clean Cruise–Blast Transitions

Testosterone Propionate's ester clearance kinetics make it uniquely suited to protocol periodisation. When an athlete steps down from a blast into a cruise, NordiTest P at 150 mg/ml allows precise dose reduction — a 0.67 ml draw delivers exactly 100 mg, a clinically relevant cruise anchor dose documented in testosterone-replacement literature. NordiTest P supports the HPG axis suppression characteristic of blast phases while its short pharmacokinetic tail means endogenous testosterone suppression depth can be modulated more responsively than with depot esters. The blast phase itself benefits from consistent EOD or three-times-weekly injections that maintain supra-physiological plasma concentrations confirmed by plasma testosterone reference ranges established in endocrinology practice.

Cruise Phase Execution: Dose Anchoring and Hormonal Stability

During the cruise phase, total weekly testosterone load is deliberately reduced to minimise aromatase substrate, manage cardiovascular strain markers such as haematocrit and LDL-C, and allow androgen receptor sensitivity partial restoration — a mechanism supported by radioreceptor binding studies showing AR density recovery correlates with time below saturating androgen concentrations. NordiTest P's 150 mg/ml concentration means smaller oil volumes per injection, reducing the local tissue burden associated with frequent administration across a multi-month cruise-to-blast cycling programme. Nordi Pharma subjects each batch to in-process HPLC concentration verification ensuring the declared 150 mg/ml is confirmed analytically, not inferred from raw API input alone.

Transitioning from Cruise to Blast

The shift from cruise to blast with propionate is executed by incrementally increasing the per-injection dose across two to three injection intervals, allowing plasma levels to step up in a controlled, auditable manner rather than the abrupt concentration spike possible with a long-ester loading dose. Nordi Pharma's fill accuracy standard supports this granular dose architecture by ensuring vial-to-vial concentration consistency across a full 10 ml supply.

Usage

Determine your cruise weekly dose (commonly 100–150 mg) and confirm your blast target dose in advance to allow accurate volume calculations at 150 mg/ml before drawing.
During cruise phase, draw the precise volume into a 1 ml syringe using a fresh 21–23G draw needle; switch to an injection needle (23–25G) before administration to maintain sterility.
When transitioning into a blast, increase the per-injection dose incrementally across two to three consecutive injections rather than escalating in a single step, allowing plasma levels to ramp in a controlled progression.
Inject into a rotation of large muscle sites — gluteus maximus, vastus lateralis, or deltoid — distributing the burden across sites during the higher-frequency EOD blast schedule to reduce local tissue irritation.
During the blast phase, schedule blood work at weeks four and eight to monitor haematocrit, blood pressure, and lipid panels as objective indicators of physiological tolerance before extending or repeating the blast.
When winding down into cruise, reduce the injection dose progressively over two to three intervals, exploiting propionate's short clearance window to reach cruise-level plasma concentrations within approximately one week of de-escalation.

Warnings

Contraindications: NordiTest P is contraindicated in individuals with androgen-sensitive carcinoma of the prostate or breast, polycythaemia, untreated severe obstructive sleep apnoea, or hypersensitivity to any component of the formulation including the carrier oil. Women of childbearing potential should not use this product due to virilisation risk.

Side Effects: Androgenic effects including accelerated androgenic alopecia, acne, and elevated sebum production are dose-dependent. Oestrogen-mediated effects — gynaecomastia and fluid retention — may emerge during blast-phase exposures and are manageable with aromatase inhibitor adjuncts. Elevated haematocrit from erythropoietic stimulation represents the primary cardiovascular concern during prolonged or high-dose blast phases. Injection-site reactions are possible with frequent EOD administration.

Monitoring: Haematocrit, haemoglobin, PSA, blood pressure, and fasting lipid panel should be assessed before starting each blast phase and at four-to-eight-week intervals during active use. Liver enzymes, while generally not a primary concern with injectable testosterone, warrant baseline assessment. Testicular volume monitoring is advisable in users who prioritise fertility, as HPG axis suppression is sustained across both cruise and blast phases.

PCT: Owing to propionate's short ester, HPG axis recovery with a SERM — typically tamoxifen or clomiphene — can commence within three to five days of the final injection if fully cycling off. Athletes using a continuous Cruise & Blast model without full cessation should consult an endocrinologist regarding long-term HPG suppression management, as standard PCT framing does not apply to ongoing protocols.

Frequently asked questions

What does the Cruise and Blast protocol mean for Testosterone Propionate users?: Cruise and Blast is a long-term androgen periodisation strategy alternating between a low-dose cruise phase — maintaining testosterone at near-physiological levels — and a higher-dose blast phase designed to maximise hypertrophic stimulus. Testosterone Propionate is favoured for this framework because its short ester clearance window allows dose escalation and reduction to reflect in plasma within days, enabling genuinely distinct phase boundaries rather than pharmacokinetic overlap.
How long should the cruise phase last before switching back to a blast?: Most structured Cruise & Blast programmes allocate cruise phases of eight to twelve weeks to allow meaningful hormonal and cardiovascular biomarker recovery between blasts. Haematocrit normalisation and LDL-C stabilisation are commonly used clinical markers to gauge cruise phase adequacy before re-escalation. With propionate, a twelve-week cruise followed by an eight-to-ten-week blast represents a well-documented periodisation ratio in performance-medicine literature.
When is the right time to transition from a blast back to a cruise with NordiTest P?: The transition from blast to cruise is typically triggered either by a pre-planned cycle calendar or by monitoring markers such as rising haematocrit, elevated blood pressure, or subjective recovery decline. Because NordiTest P contains the short propionate ester, the dose reduction takes effect within two to three injection intervals, allowing athletes to enter cruise-level plasma concentrations rapidly without a prolonged washout window required by depot esters.
How does NordiTest P's 150 mg/ml concentration benefit frequent injections during a blast phase?: At 150 mg/ml — the highest concentration in this product group — each injection delivers more active compound per millilitre of oil, reducing the total volume administered per session. For athletes injecting EOD or daily during a blast, this translates to reduced injection-site accumulation and lower local tissue stress compared to 100 mg/ml formulations requiring proportionally larger draws to achieve the same dose.
How should NordiTest P 10 ml vials be stored and handled for multi-week cruise and blast protocols?: Store NordiTest P vials at room temperature between 15–25 °C, away from direct light and moisture; refrigeration is not required but the vial should never be frozen. Once punctured, standard multi-dose vial sterility guidelines recommend use within 28 days with each draw executed using a fresh sterile needle to maintain septum integrity. An insulin syringe can accurately measure the 0.1 ml increments that correspond to 15 mg at this concentration. (2) angle_used

Manufacturer

Nordi Pharma's ester specialisation strategy is visible in how NordiTest P is developed as a formulation engineered specifically around the physical and pharmacokinetic properties of the propionate ester rather than adapted from a generic testosterone-injectable template. Propionate presents distinct solubility behaviour and viscosity characteristics compared to longer-chain esters, and Nordi Pharma addresses this through ester-specific compounding parameters — carrier-oil selection, concentration targets, and filtration specifications — validated during product development rather than inherited from other ester formulations in the portfolio. This specialisation extends to analytical release testing: each NordiTest P batch is evaluated by HPLC potency assay calibrated to the declared 150 mg/ml specification, with acceptance criteria that are ester-specific rather than applied universally across all testosterone formats. LAL endotoxin assay results must fall within defined limits before batch release authorisation, providing an independent sterility-assurance checkpoint that is particularly relevant for a product intended for high-frequency administration during blast-phase protocols.

Product details

Brand	Nordi Pharma
Active ingredient	testosterone propionate
Also known as	Testosterone Propionate, Test P, Testovis, NordiTest P, Nordi Pharma Testosterone Propionate
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TPRO-NOR-150-016

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsMiles4Verified purchaseJul 16, 2026
Prop done right
Running 150mg EOD as part of a cut, 8 weeks in and strength is still climbing despite being in a deficit. Bloods at week 6 showed test at 1840 ng/dl, hematocrit sat at 46 which is fine. PIP was basically nothing after the first couple of shots, oil is smooth and flows easy through a 25g. Packaging came through completely discreet, nothing on the outside to raise eyebrows. Genuinely one of the better prop vials I've used.
Rating: 4 out of 5 starscarbon10Verified purchaseJun 12, 2026
Good prop, minor PIP
Solid product overall, test levels came back strong at week 4 and pumps in the gym are mental. Only gripe is the first 3 or 4 injections had decent PIP in the quad, nothing unbearable but enough to notice. Switched to glutes and it was fine after that. Would order again without hesitation, just worth knowing if you're new to prop.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Propandrol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Propandrol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Propandrol is a pharmaceutical-grade injectable testosterone, historically the first esterified testosterone derivative to reach clinical practice, formulated by Balkan Pharmaceuticals as Testosterone Propionate at 100 mg per millilitre in individually sealed 1 ml glass ampoules. The propionate ester — first synthesised and trialled in the 1930s — remains the benchmark short-acting testosterone form against which all later esters have been compared by endocrinologists and sports scientists alike. Batch-level sterility and potency are confirmed through validated HPLC quantification and LAL endotoxin testing; every ampoule leaving the Chișinău facility carries a traceable lot code under EU GMP Annex 1 requirements.

€36.00

Optimal Dosage

Propha-Testosterone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Testosterone by Beligas Pharmaceuticals supplies Testosterone Propionate at 100 mg/ml in a sterile 10 ml multi-dose vial — an intramuscular injectable whose short-ester architecture routes the compound directly into systemic circulation, bypassing the hepatic first-pass degradation that renders oral testosterone formats pharmacokinetically inferior. Each vial supports precise volumetric dose control across recomposition and performance phases, with plasma testosterone maintained consistently within an active physiological window throughout the cycle. Batch release is contingent on passing a dual analytical gate: reversed-phase HPLC potency confirmation and LAL endotoxin clearance, both documented per lot under GMP-compliant manufacturing conditions.

€35.00

Testopin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Testopin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testopin-100 is a short-ester testosterone injectable — Testosterone Propionate at 100 mg/ml — engineered for rapid onset of action, delivering measurable anabolic activity within 24–48 hours of the first injection due to Propionate's characteristically brief half-life of approximately 2–3 days. Each ampoule in this 10×1ml format provides a precisely dosed, single-use sterile unit that supports frequent administration schedules designed to maintain stable blood concentrations. Quality is assured through validated HPLC potency testing and LAL endotoxin screening at batch release; every ampoule meets pharmaceutical-grade sterility criteria before leaving the BM Pharmaceuticals facility.

€38.00

High Concentration

PropiTrex 150mg/ml 10ml Vial by Concentrex Labs

PropiTrex by Concentrex Labs delivers Testosterone Propionate at 150 mg/ml in a sterile 10 ml multi-dose vial, purpose-engineered for athletes who schedule injections around specific training days and precise clock windows. Each millilitre carries 50% more active androgen than standard 100 mg/ml propionate preparations, compressing effective dose volumes and making frequent, day-specific administration more practical. Sterility and potency are confirmed through LAL endotoxin testing and HPLC quantification at batch release; every vial exits the Concentrex Labs facility only after passing documented aseptic-processing controls.

€35.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00